On November 22, 2024, President-elect Donald Trump announced key appointments for his administration's public health positions, nominating Dr. Marty Makary as FDA Commissioner, Dr. Janette Nesheiwat as U.S. Surgeon General, and Dr. Dave Weldon as CDC Director.

Makary, known for his criticism of COVID-19 measures, aims to restore scientific standards at the FDA and reduce bureaucratic delays in delivering medical treatments.

Trump expressed confidence that under Makary's leadership, the FDA will improve its reputation in scientific research and streamline processes for medical treatments.

Dr. Dave Weldon, nominated as CDC Director, has a history of involvement in health policy, particularly regarding vaccine safety and regulation.

As Surgeon General, Nesheiwat will oversee the U.S. Public Health Service Corps and issue health advisories that can significantly influence public health responses.

The FDA, which oversees the safety and effectiveness of drugs and medical devices, plays a crucial role in U.S. consumer spending, accounting for about 20% of it.

All nominees for these key health positions will require Senate confirmation before taking office.

These appointments reflect a shift towards conservative ideologies in public health policy, particularly concerning vaccination and drug regulation.

Makary's leadership may lead to a shift towards stricter drug approval processes, reversing the trend of expedited approvals influenced by industry lobbying.

A professor at Johns Hopkins University, Makary gained prominence during the pandemic for his opposition to vaccine mandates and skepticism about certain public health measures.

If confirmed, Makary will report to Robert F. Kennedy Jr., Trump's pick for the Department of Health and Human Services, who shares some skepticism about the pharmaceutical industry.

Kennedy has proposed controversial changes, such as halting pharmaceutical advertising and ending FDA funding from drugmaker fees, which could face significant legal and financial challenges.